MEX3A is a new diagnostic, independent prognostic biomarker and a promising therapeutic target in gliomas
Preprint in Research Square (May 2024)
The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.
Post-translational protein lactylation modification in health and diseases: a double-edged sword
Article in Journal of Translational Medicine (January 2024)
Patient-derived primary culture-based prognostic model to predict tumor recurrence in patients with glioma
Article in Advances in Biomarker Sciences and Technology (January 2024)